Human ESCs represent a promising source for cellular replacement therapies owing to their availability, pluripotency, and unlimited selfrenewal capacity. However, they also carry risks of neoplastic change, uncontrolled proliferation, and differentiation to inappropriate cell types 1,2 . The eye is advantageous in investigating hESC-based cell therapy as it is accessible and confined, and the transplanted cells can be monitored directly in vivo, with the possibility of being removed or destroyed if there is evidence of neoplastic change 3,4 . Furthermore, long-term immunosuppression can be delivered locally.
cell loss, cell distribution within the eye, and physical damage to the RPE monolayer.
The clinical trial was designed as a phase 1, open-label, safety and feasibility study of implantation of an hESC-RPE patch in subjects with acute wet AMD and recent rapid vision decline. For safety reasons and to obtain an early efficacy signal, the trial involved patients with severe wet AMD only, although we aim to study the RPE patch in early dry AMD in the future. We reported three serious adverse events to the regulator. These were exposure of the suture of the fluocinolone implant used for immunosuppression, a retinal detachment, and worsening of diabetes following oral prednisolone. All three incidents required readmission to the hospital, with the first two incidents requiring further surgery and the third being treated medically. The three incidents were treated successfully. Both patients achieved an improvement in best-corrected visual acuity (BCVA-vision with an optometrist-determined best glasses-corrected vision) of >15 letters at 12 months after transplantation.
RESULTS

Engineering an RPE patch
Our protocol for manufacturing a clinical-grade RPE patch is summarized in Figure 1 . RPE cells were differentiated from the SHEF-1.3 hESC line, which had been derived from the SHEF-1 hESC line. We used a spontaneous differentiation method 10 , an approach that has been described earlier by others and has been applied to primate 11 and human 12, 13 ESCs. Spontaneous differentiation limits the need for additional factors, facilitating compliance with good manufacturing practice (GMP) guidelines, and with clear advantages over vectordriven methods in terms of the safety and stability of the final RPE. Our differentiation protocol differs from another similar protocol 10 in that we used Essential 8 medium rather than human feeder cells during expansion and the early phase of differentiation to avoid exposure to another cell type and to fulfill GMP guidance. While several methods are used to produce hESC-RPE 11, [13] [14] [15] , because of epigenetic variation from the earliest stages after derivation of hESCs, no method is universally effective 15, 16 . With our protocol, 20-30% of hESC colonies differentiated to RPE (data not shown), which is a similar rate to that of other spontaneous methods 11, 13 but less efficient than some augmented methods [15] [16] [17] .
Subsequent RPE characterization ( Fig. 2 ) used immunocytochemistry ( Fig. 2a) , electron microscopy ( Fig. 2c) , pigmentepithelium-derived factor (PEDF) secretion profile testing (Fig. 2b) , and a functional phagocytosis assay (Fig. 2d) . During manufacturing, in-process testing, including in situ hybridization with a specific oligonucleotide probe for LIN28A mRNA 12 , was undertaken to detect hESC impurity at the single-cell level. Differentiated RPE was discarded if any LIN28A-positive cells were detected. The hESC-RPE cells were seeded at confluence onto a human-vitronectin-coated polyester membrane. A 6 × 3 mm (17 mm 2 ) therapeutic element with ~100,000 cells (PF-05206388 in the regulatory documentation) was cut to size with a purpose-built punch and loaded into a sealed transport container (Fig. 1) . Immediately before release for human transplantation, the cell layer was recharacterized as RPE by means of a visual inspection release test encompassing cell dose, cell identity, and patch coverage checks.
Mouse teratoma and in vitro cell-spiking studies
We tested tumorigenicity of the hESC-RPE in NIH III nude mice ( Fig. 3a-e) . Cell suspensions were used as the mouse eye is too small to administer a patch. Two initial studies conducted with undifferentiated hESCs showed that teratomas could form. In these studies, cell suspensions were injected subretinally, intramuscularly and • VIR test • Sterility, endotoxin, and mycoplasma
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Plasma-derived vitronectin hESC differentiation hESC-RPE isolation and expansion hESC-RPE patch as an ATMP Figure 1 Generation of hESC-derived RPE for the manufacture of an advanced therapeutic medicinal product (ATMP) to treat AMD. This figure outlines the chronological process for manufacturing the RPE patch from SHEF-1.3 hESCs. The first four rows show: the stages of differentiation; the coating on the plasticware for each step; the media used at each step; and the tests and checks performed at each step. The bottom row shows brightfield images illustrating each stage: (i) hESC colonies expanded on recombinant human vitronectin (VTN-N); (ii) Spontaneously differentiated RPE cells appear as distinct pigmented foci; (iii) These foci are manually dissected, dissociated, and filtered to achieve a pure single-cell-type RPE population, which is seeded onto plates, where expanding RPE cells establish their classic pigmented, cobblestone morphology; (iv) Fully differentiated RPE-seeded at confluence onto a human-vitronectin-coated PET membrane transwell insert; (v) A therapeutic patch consisting of the RPE monolayer immobilized on the vitronectin-coated PET membrane that has been cut from the transwell; (vi) Following release tests, the advanced therapeutic medicinal product is supplied to the surgical team in a custom-manufactured, single-use sterile container in saline, where it is viable for up to 8 h. PMEL17, premelanosome marker 17; ICC, immunocytochemistry; ISH, in situ hybridization; PET, polyethylene terephthalate; VIR test, visual inspection release test.
A r t i c l e s subcutaneously, with mice followed for 26 weeks. Subsequently, we studied the tumorigenicity of hESC-RPE cells under good laboratory practice (GLP) conditions, including a positive control group injected with undifferentiated hESCs. Given our finding that undifferentiated hESCs formed teratomas, we conducted in vitro cell-spiking studies to examine whether hESCs survive the RPE manufacturing process and culture-seeding conditions. In the first study, injection of 4.5-8.8 × 10 4 undifferentiated hESCs into the subretinal space of NIH III mice resulted in localized neoplastic formation in almost half the males injected (12/30) but in very few females (2/30). The tumors showed evidence of pluripotency and appeared to be composed of mesenchymal and epithelial lineages (data not shown).
In the second study of undifferentiated hESCs, neoplastic masses were observed in the injected eye of 12/15 female and 5/5 male mice after cell administration into the subretinal space. Teratomas were observed microscopically in the thigh of all female mice that received 3.6 × 10 4 or 8.23 × 10 5 undifferentiated hESCs in BD Matrigel by the intramuscular route, and in the left flank of 2/5 and 1/11 female mice that received 3.6 × 10 4 or 8.23 × 10 5 undifferentiated hESCs in BD Matrigel, respectively, by the subcutaneous route. Masses were composed of structures derived from all embryonic germ layers (data not shown).
In the third study, conducted with cells manufactured under GLP conditions, suspensions of hESC-RPE cells, or of undifferentiated hESCs as a positive tumorigenic control, were injected subretinally in NIH III mice. In a total of 80 mice injected with suspensions of hESC-RPE cells, no teratomas were detected (Fig. 3b) . Pigmented hESC-RPE cells were observed lining the surface of the retina or lens in the injected eyes of some mice given 6.04 × 10 4 hESC-RPE cells (Fig. 3e, i ,ii,iii) at 26 weeks.
In the same study, administration of undifferentiated hESCs was associated with ocular teratoma formation in four males and five females given 4.28 × 10 4 cells, all of which were prematurely euthanized (between days 46-62), and in a single male given 4.51 × 10 3 cells, which survived to the 26 week end point of the experiments. (Fig. 3c) . In addition, mesenchymal tumors classified as "Not Otherwise Specified" were present in two males given 4.28 × 10 4 undifferentiated hESCs (Fig. 3d) and perilenticular mesenchymal hyperplasia in animals of both sexes given 4.51 × 10 3 cells or 4.28 × 10 4 cells. All tumors were composed of human cells, as confirmed by immunohistochemistry using an anti-human mitochondrial marker (data not shown). Eyes injected with undifferentiated hESCs also exhibited an increase in the incidence and severity of non-proliferative changes, including lenticular degeneration, posterior synechiae of the iris, and , demonstrating hESC-RPE phagocytosis. The extent of phagocytosis was also examined after treatment of the hESC-RPE with MERTK antibody (hESC-RPE + blocker). Data shown are mean internalized POS ± s.e.m. (n = 3 biologically independent cell cultures in each group). Pre-incubation with MERTK antibody had a significant effect on the number of POS ingested by hESC-RPE (P = 0.0000103075196107, two-tailed Student's t-test). This was a single experiment with no replication. Below the graph, confocal micrographs show the internalized POS with a green fluorescent marker (POS) in hESC-RPE and its relative absence in hESC-RPE with MERTK antibody (hESC-RPE + blocker).
retinal detachment (data not shown). Transplantation of either differentiated or undifferentiated hESCs did not affect body weight. Given the tumor formation observed with undifferentiated hESCs, we aimed to determine whether hESC-RPE contained any residual pluripotent cells or could support the survival of pluripotent cells, as this would constitute a teratoma risk. Using immunostaining and flow cytometric analysis of cells expressing the pluripotency marker Tra-1-60 (Abcam 16288, Cambridge, UK), we detected no undifferentiated hESCs in dissociated RPE foci before the expansion phase or at 6 to 8 weeks after seeding at the end of the expansion phase (Supplementary Fig. 2 ). We spiked undifferentiated hESCs into the RPE at 1, 10, 20, or 50% of total cells at the start of the expansion phase. This did not affect the quality of the resulting 6-to-8-week-old cultures at the end of the expansion phase, which showed cobblestone morphology and pigmentation, and stained strongly for PMEL17 (an RPE marker that indicates the presence of premelanosomes). By 2 d post-spiking, viable Tra-1-60-positive cells were no longer detectable by flow cytometry (data not shown). This finding was supported by propidium iodide staining, which showed that ~96% of hESCs died when dissociated and seeded in the same manner as RPE prepared for expansion ( Supplementary  Fig. 3 ). The cells that survived in some experiments did not have hESC-like morphology and failed to stain for Tra-1-60 or the proliferation marker Ki67, suggesting that they had differentiated or senesced ( Supplementary Fig. 3d,e) .
Pig single-dose studies Studies of surgical feasibility and safety of delivery of the RPE patch as well as studies of local and systemic biodistribution and toxicity were carried out in pigs (Fig. 3f-k) . Human and pig eyes are similar in size, which allowed for administration of the full-size patch. Two studies were performed; the second used the same clinical surgical technique as in the human clinical trial. Biodistribution of hESC-RPE cells was evaluated in more than ten sites using qPCR detection of multiple human cell markers.
In the first pig study, patch delivery was successful in all 20 animals, as assessed by intraoperative observation of the patch under the neural retina and histological sections showing the patch in the A r t i c l e s subretinal space (Fig. 3h,i) . No retinal detachments were noted in any animal. We found surviving human cells by light microscopy at 2 h, 2 d, and 1, 2, 4, and 6 weeks after implantation (RPE patch: n = 12; control patch without cells: n = 8; figure 3 H-K). Human cell survival was demonstrated despite immunosuppression having been limited to the peri-operative period using oral prednisolone. Surviving cells remained pigmented (Fig. 3f,j) . Cells expressed RPE-specific cell markers, showed no proliferation activity, and did not migrate away from the membrane (data not shown). Photoreceptor survival above the patch was observed only in animals that received an RPE patch, as assessed by histology (Fig. 3h) . The control membrane without cells did not support photoreceptor survival (Fig. 3i) . Microscopically, retinal architecture was intact in most animals receiving human cells. Macrophages were seen and appeared to have phagocytosed some transplanted RPE cells to form large pigmented cells (data not shown). Lymphocytic infiltrate was not observed except in 2 animals at 2 and 6 weeks. Animals that received the control membrane also had macrophage infiltrates but no lymphocytic response (data not shown). These results demonstrated that patch transplantation with hESC-RPE survival was surgically feasible without significant safety issues. The second pig study differed from the first in that we used the purpose-built surgical tool, which has a protective cradle at the tip from which the patch is mechanically pushed out when the tip is in the subretinal space (Supplementary Fig. 1 ). The study was undertaken under GLP conditions, a standardized set of requirements to ensure quality and systematic management of the experiment. In this case, it dictated standards for the operating and animal facilities and for the personnel who ran the trial, and defined the conditions and requirements for the keeping and monitoring of animals in the study, including the feeding regimen. Correct surgical delivery of ten RPE patches and ten coated membranes without RPE was achieved in 20 pigs as assessed by clinical examination and histology (Fig. 3f,g ). Good cell cover was observed at the 6-week time point in the ten animals that received RPE cells (Fig. 3f) . Retinal detachment and rupture of the lens capsule were observed in one male and one female implanted with the patch. There was no evidence of weight loss or early death in any animal. At 6 months after implantation, no hESC-RPE cells were detected at the implantation site or elsewhere in H&E sections of the ten eyes receiving the RPE patch. Anti-human TRA-1-85 immunostaining of the operated eye and optic nerve from these animals was also negative. Microscopic findings of chronic inflammation were seen restricted to the subretinal implantation site, at 6 months in the implanted (left) eye of all animals, and were consistent with the intraocular surgical implantation procedure. The microscopic findings included fibrosis, osseous metaplasia, and small numbers of macrophages and multinucleate giant cells (data not shown). Atrophy of the photoreceptor layer in overlying retina was also present (data not shown). Findings were of similar incidence and severity in both control and cell-treated animals. No positive amplification of any human-specific genes was observed in adrenal, bone marrow (rib and femur), brain, heart, kidneys, liver, lungs, lymph nodes, optic nerve, spleen, or thymus, which were evaluated by qPCR, indicating that the cells did not appear to migrate or survive away from the site of implantation. The second pig study confirmed the surgical feasibility and reliability of the delivery tool and the lack of systemic or local distribution of the hESC-RPE cells.
Clinical trial
Regulatory permission was granted for a phase 1 clinical trial on the basis of the preclinical surgical, safety and tumorigenicity studies reported in this article and published data on the hESC-RPE monolayer 9 (Clinicaltrials.gov: NCT01691261). Permission was granted for ten patients, and we report the primary and secondary outcomes from . In addition to safety, the trial investigated whether the synthetic membrane would facilitate mechanical delivery of the RPE monolayer, whether the transplanted cells could be sustained long-term with local immunosuppression only, and whether early signals of potential efficacy were evident. Using the surgical delivery tool, we placed one RPE patch in the subretinal space, under the fovea, in the affected eye of each patient. Correct placement was confirmed in both patients by stereobiomicroscopy, fundus photography, and spectral domain optical coherence tomography (SD-OCT) (Figs. 4b, i,ii and 5b, i,ii).
In patient 1, OCT and native-level autofluorescence immediately after surgery showed a 'double thickness' of RPE in one area nasal to the fovea, indicating overlap of native RPE and the patch (Fig. 4b,c,e) . In all other areas in patient 1, and in all areas in patient 2, a single layer of RPE on OCT suggested there was no residual native RPE over the patch (Figs. 4b, ii and 5b, ii). In both patients, hESC-RPE was present over the full area of the patch at 12 months as evidenced by dark pigmented cells covering the patch, although unevenly, photos of the fundus, and a hyper-reflective monolayer on the patch seen by SD-OCT (Figs. 4b, i,ii and 5b, i,ii and 6a,b). In both patients, the patches showed uneven autofluorescence (Figs. 4e, iii and 5e, iii), which suggests functioning RPE phagocytosis 18, 19 . Also, visible in both patients were darker, pigmented areas continuous with the patch, which may represent RPE cell migration off the patch onto adjacent RPE-deficient areas. These areas spread from the patch edge outward over the first 6 months after surgery before stabilization (Fig. 6a,b) . The areas were contiguous with the patch RPE signal on OCT and were absent in areas where the native RPE layer persisted. There was no evidence of neoplastic transformation either on regular review of the fundus by an ocular oncologist or by serial ocular ultrasound.
In addition to RPE survival, we studied visual recovery in both cases. Testing was always carried out by an independent qualified observer. The Early Treatment Diabetic Retinopathy Study (ETDRS) letter chart was used to define BCVA, which improved over 12 months from 10 to 39 and from 8 to 29 letters, in patients 1 and 2, respectively (Fig. 7a,c) . Microperimetry, a test of perception of microlocalized light stimuli, showed visual fixation at the center of the patch and vision over the patch in both patients at
b ii 520 µm 520 µm . We note that it was not possible to ascertain whether the ellipsoid zone was present pre-operatively, owing to the poor detail in the pre-operative OCT scans (Figs. 4a, ii and 5a, ii). Rtx1 adaptive optics camera images showed survival of cone photoreceptors in the areas corresponding to areas of sensitivity on microperimetry (Figs. 4d, i and 5d, i) . We reported three serious adverse events that were unrelated to the RPE patch. The first was exposure of the suture of the fluocinolone implant in patient 1, which required conjunctival revision surgery. The other two, both in patient 2, were a worsening of diabetes following oral prednisolone, which was treated medically, and a retinal detachment. The retinal detachment was an asymptomatic, infero-temporal, proliferative vitreoretinopathy (PVR)-associated traction retinal detachment under silicone, which did not extend past the inferior arcade and thus did not affect the implant. It was observed at the 8-week follow-up, with the retina having been completely attached at the 4-week check. It was treated with a single surgery with peeling of the PVR membranes, inferior retinectomy of the peripheral retina (180 degrees), and laser to the retinectomy edge. The silicone oil was retained. The retina was attached at the end of the surgery and has remained attached after subsequent surgery to remove the silicone oil. There was a residual epiretinal band over the posterior pole with some focal macular traction (Figs. 5b, i  and 6b) , which was not treated.
Ocular pressures were never raised in either patient. No changes of concern were noted in the liver and renal function tests and by liver ultrasound in either patient. On full-field electro-retinography (ERG) recording, there was evidence of a mild but consistent reduction in photoreceptor function at 6 months in both patients with additional consequent electro-oculography (EOG) reduction (in the eyes operated on). The reduction in photoreceptor function persisted in patient 1 but recovered in patient 2 by 12 months.
DISCUSSION
The results presented here provide an early indication of the safety and feasibility of manufacturing an hESC-RPE monolayer on a synthetic basement membrane and delivering the patch into the subretinal space as a potential treatment for AMD. Our data suggest early efficacy, stability, and safety of the RPE patch for up to 12 months in two patients with severe vision loss from very severe wet AMD.
hESC-RPE on a membrane shows optimized differentiation, polarization, viability, and maturation of the monolayer at the time of delivery that contrasts favorably with delivery of cell suspensions, where the cells are necessarily not in a monolayer and thereby not polarized or fully differentiated. Proper orientation is readily confirmed by the color difference between the white membrane and the pigmented RPE. Cells delivered in suspension may be lost due to reflux through the retinotomy, with potential vitreous seeding, and the cells undergo shear stress and damage when ejected through the delivery cannula 21 . Furthermore, cells in suspension are required to adhere to and form a monolayer on a damaged native Bruch's membrane, which leads to poorer cell survival and widespread apoptosis 22 . Previous work showed poor differentiation using suspensions and that RPE monolayers on membranes appear superior 23 .
Therapeutic human RPE patch transplantation has been reported using a harvested autologous RPE-Bruch's membrane-choroid patch from the same eye [24] [25] [26] and an induced pluripotent stem cell (iPSC)-derived RPE patch 9 . The main advantages of our system over these are mechanical ease of handling due to the rigidity of the synthetic membrane. The tool we developed also allowed consistent patch delivery with a small localized retinal detachment over the macula, whereas with the intraoperative harvested autologous technique, half of the entire retina must be reflected to ensure consistent delivery without RPE damage 27, 28 . The availability of an off-the-shelf patch would be especially advantageous and critical in cases of severe wet AMD with sudden vision loss, as described in this study. Treatment is required rapidly 29 , and an autologous iPSC patch could not be prepared in a suitable time frame for transplantation. It is also possible that the hESC-RPE patch may alter the natural history of the disease as the cells are zero years old, rather than the 60-plus years of the patients, and are not genetically or environmentally predisposed to develop AMD; however, only further investigation can address this. The main disadvantage of our technology is the need for immunosuppression, although for the two cases reported here we have demonstrated that only local immunosuppression was necessary for long-term hESC-RPE survival.
We present the preclinical safety and tumorigenicity studies that supported regulatory approval of our clinical study. The literature suggests that adult human RPE cells 30 , terminally differentiated hESC-RPE 31 , and spontaneously immortalized RPE cells 32 are nonproliferative cell types and appear to lack the potential to form teratomas. The GLP study of tumorigenicity in NIH III mice showed that the hESC-RPE was not associated with tumor formation or other notable proliferative changes. A r t i c l e s formation as well as unclassified mesenchymal tumors, peri-lenticular mesenchymal hyperplasia, and an increase in the incidence and severity of degenerative changes in the treated eye. Owing to tumor formation by undifferentiated hESCs, a major safety concern was the potential for survival and persistence of undifferentiated hESCs through the manufacturing process. In-process testing for undifferentiated cells is essential in the manufacture of any cell product from pluripotent cells for human transplantation. Spiking studies and single-cell labeling studies demonstrated no detectable undifferentiated cells in the final product. Even when we contaminated primary foci of hESC-RPE cells with up to 50% undifferentiated hESCs, no pluripotent hESC cells were present by the end of the expansion phase. Furthermore, hESCs were not viable when dissociated and seeded into RPE expansion conditions. Thus, we demonstrated that undifferentiated hESCs were not detectable at stage 4 of the production process, and that the RPE differentiation medium does not support the survival of hESCs.
Our preclinical studies in pigs investigated surgical feasibility, biodistribution, and toxicity. We showed consistent facilitated mechanical delivery of the RPE patch in all 20 pigs operated on in the GLP final study using our purpose-built tool. Implantation of the control membrane without cells led predictably to a foreign body reaction, but this was minimal when RPE cells covered the membrane. The presence of RPE was also associated with persistence of the native photoreceptor layer and less retinal atrophy than membrane alone in both pig and clinical studies.
A qPCR analysis of systemic biodistribution in pigs at 26 weeks after implantation of one clinical-sized graft (~100,000 hESC-RPE cells) showed no evidence that cells migrated or survived away from the site of administration. The lack of distribution of the cells is consistent with previous studies on ocular administration of RPE cells 32 . This is also supported by our NIH III mouse study, in which teratomas from undifferentiated hESCs were found only in the eye, where the cells had been administered, and not in tissues distal to the site, suggesting that undifferentiated hESCs do not migrate or do not survive away from the site of implantation.
In the GLP pig study with no immunosuppression, no definitive hESC-RPE cells were identified at 26 weeks, whereas persistent hESC-RPE cells were found at 6 weeks in the earlier pig studies (in which some animals were immunosuppressed perioperatively), and at 26 weeks in the NIH III mouse teratoma studies (immune-deficient animals). Histology of the implanted patch at 6 weeks from animals in the first pig study showed persistence of human RPE and support of normal retinal architecture relative to animals receiving the membrane alone. Microscopic findings consistent with a localized chronic inflammatory reaction around the polyester membrane were present in animals from both groups in the GLP pig study at 6 months, in the absence of any RPE cell cover. There was no difference in the incidence or severity of the inflammatory reaction in either group.
In the clinical trial, the transplanted RPE patch survived, as demonstrated by a clear RPE signal on OCT for 12 months and the visible persistence of a pigmented cellular monolayer, although some of these cells may have been pigmented macrophages. There was evidence of early autofluorescence in both patients 1 and 2, suggesting that RPE phagocytosis has commenced 18, 19 . The retina over the patch was thinned in patient 1 but not in patient 2, which may reflect a difference in pre-operative disease or level of microtrauma from manipulation during surgery. It is possible that the decrease in central pigmentation in patient 1 represented cell loss from delayed rejection. Both patients retained features of normal architecture and visible areas of the ellipsoid zone. Furthermore, there was clear evidence of retinal function over the patch, as demonstrated by fixation microperimetry, which showed focal sensitivity, and increased visual acuity and reading speed, all of which were sustained or improved over 12 months post-transplant. However, in the absence of a control, proving the improvement was due to the transplant is not possible. The improvement in reading exceeded that of similar cases in the Submacular Surgery Trial 20 . Visual function remained variable across the transplanted area, with poor visual function and thinning centrally in patient 1, which we feel may reflect intra-operative surgical trauma.
While histological evidence of hESC-RPE survival was not possible, the extensive number of structural and functional features discussed above support the conclusion that the hESC-RPE survived. Furthermore, the presence of transplanted hESC-RPE cells immediately adjacent to the neuroretina suggest that they are associated with retinal function over the patch. We did not intentionally remove the subretinal choroidal neovascular membrane, but cannot exclude that it was removed inadvertently. Therefore, the effect of the original choroidal neovascular membrane on function remains ambiguous. However, the co-localization of choroidal perfusion, survival of hESC-RPE, retinal sensitivity, and presence of photoreceptors strongly support the conclusion that the visual improvement and stability was associated with the transplanted RPE patch.
Retinal detachment was the most severe clinical complication seen. The GLP pig studies had two retinal detachments in 20 animals, which is similar to the rates reported for early human autologous transplantation and translocation surgeries 33, 34 . The retinal detachment in patient 2 of the clinical trial was likely a PVR-associated detachment that occurred between 4 and 8 weeks. It was treated with a single operation using standard techniques. The retinal detachment did not extend far enough to reach the patch. However, despite the delivery of RPE cells on a patch and in a protected delivery device, both of which minimize the shedding of RPE cells into the vitreous, we cannot be certain that no hESC-RPE cells were released nor that they did not contribute to the risk of developing PVR. The true surgical risk can be assessed accurately only with a larger series of patients.
In patient 1, there was an area of native RPE over the patch that was clearly delineated and separate from the large area over the patch where the native RPE was lost and only hESC-RPE was present. Notably, the patient fixated not over native RPE but over the RPE patch. Subjectively, patient 1 acknowledged that her vision improved relative to the preoperative state and that she could see letters and read directly with the central vision; however, she described troublesome distortion, similar to that experienced by patients who have had previous retinal detachment or wet AMD. The second patient described his vision as continuously improving but also being "dimmer" than before the onset of the disease, which is consistent with his longer-standing disease at presentation and, likely, more damaged neuroretina.
Reporting these first two cases at 12 months is valuable because the functional improvement, robust imaging data, lack of major safety concerns, and demonstration of sufficiency of local immunosuppression represent steps in support of hESC-based regenerative therapy for AMD and other diseases of the eye. We show that differentiation of hESCs into a therapeutic cell with delivery, survival, and rescue of vision in very severe disease is feasible. Although 12 months is sufficient to begin to describe cell survival and clinical outcomes, it is early in terms of safety monitoring, especially for late teratoma formation. The patients will be followed for five years after surgery. These two early cases are also instructive as they show an encouraging outcome despite very advanced disease, which increases the complexity of surgery and involves moredamaged neuroretina. Additionally, there was no evidence of recurrence A r t i c l e s of the neovascular membrane and no need to administer angiogenesis inhibitors to either patient at 12 months, although with only two cases it is difficult to attribute this to the transplant.
The role of immune privilege in the subretinal space remains ambiguous, and the immunological effect of the surgery and patch transplant is unknown. Stability of the transplant was achieved with immunosuppression consisting of perioperative oral prednisolone and long-term intraocular steroid implants. For patient 2, who has type II diabetes, there was a period of poor blood sugar control with the need to add insulin, due to the systemic steroid use. Given the concerns about long-term systemic immunosuppression, a notable finding of this study is that the transplanted hESC-RPE cells survived at least 12 months with only local immunosuppression. Although long-term, local immunosuppression can be provided in the eye without systemic side effects, the possibility of long-term ocular morbidity remains. In our two patients there was no associated intraocular pressure rise or need for pressure-reducing medication.
Stem-cell-based tissue transplantation is a potentially effective treatment strategy for neurodegenerative or other diseases with irreversible cell loss. Here we addressed challenges related to engineering, manufacturing, and delivering a clinical-grade hESC-RPE patch, leading to stabilization and improvement of vision for at least 12 months in two subjects with severe vision loss from AMD. These findings support further investigation of our approach as an alternative treatment strategy for AMD.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. reprints and permissions information is available online at http://www.nature.com/ reprints/index.html. Publisher's note: springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
A r t i c l e s The pig surgery was carried out under GLP conditions at the Northwick Park animal experimental surgery facility (Northwick Park and St Mark's Hospital, Harrow, Middlesex, UK). Pigs were cared for in an independent GLP registered facility including throughout the 6-month's follow-up period. The animal reporting including organ sampling was carried out independently by HLS.
Pfizer Inc. sponsored and was the sole funding source of the clinical trial. Two subjects out of a planned 10 were enrolled before Pfizer suspended funding for strategic commercial reasons unrelated to this trial. The cells for transplantation were prepared to the state of confluent RPE at Roslin Cells Ltd. (Edinburgh, United Kingdom,) before transport to London. The preparation and cutting of the patch was completed at Cells for Sight (Institute of Ophthalmology, Bath St., London, UK).
Approval Committee (E-DMC). The data monitoring committee had three representatives who were retinal surgeons, with two having specialty expertise in ocular oncology and the third in ocular immunology. Informed consent was obtained from each patient. The study compliance with protocol was reviewed regularly, and none of the recorded protocol deviations had an impact on subject safety or study integrity. The authors vouch for the accuracy and completeness of the data and data analyses. The datasets generated by HLS and Aros are being transferred to the academic authors.
Statistics.
The only statistical analysis reported was for the phagocytosis study (Fig. 2d) . Data shown are mean ± s.e.m., n = 3 biologically independent cell cultures in each group. As the n is less than 10, individual data points are indicated. Analysis was by two-tailed Student's t-test with P = 0.0000103075196107. This was a single experiment with no replication.
Preparation of hESC-RPE (GMP conditions and facility).
The original cell source, the SHEF-1 hESC (NIBSC -UK Stem Cell Bank -http://www.nibsc. org/ukstemcellbank) line was expanded according to GMP guidelines at the Stem Cell Derivation Facility, Centre for Stem Cell Biology (CSCB), University of Sheffield 35 . The SHEF-1 and 1.3 cell lines were authenticated by a short-term repeat analysis fingerprint, which was performed by University of Wisconsin Hospital and Clinics. The analysis showed an identical STR genotype profile across eight human STR loci for both SHEF-1 and SHEF-1.3. The SHEF-1.3 cell line was derived from the expanded SHEF-1 hESC cells under the same GMP conditions at the same facility. The passage and expansion of SHEF-1.3 hESCs was carried out in recombinant human vitronectin (VTN-N) (Life Technologies)-coated culture vessels. Medium was removed from cultures and hESCs were washed with PBS −/− (without Ca ++ and Mg ++ ), incubated with EDTA (Sigma) until the cell colonies begin to detach. Cells were resuspended in Essential 8 (E8) medium (Life Technologies) and seeded onto VTN-N-coated culture vessels. hESCs were replenished with E8 medium daily, and passaged every 3-4 d depending on visual observations of colony morphology and size. hESC differentiation to RPE was carried out in flasks coated with plasmaderived vitronectin (Amsbio). Sets underwent regular media replenishment with E8 medium for up to 14 d until hESC colonies were ~80-100% confluent and then transitioned to TLP medium consisting of 389 ml of Knockout DMEM, 1 ml of 2-mercaptoethanol, 5 ml of NEAA (non-essential amino acids), 100 ml of knockout serum and 5 ml of l-glutamine per 500 mL (Invitrogen -LifeTechnologies; Thermo Fisher Scientific). Cells were maintained on a twice-weekly media replenishment regimen. RPE cells appear in culture as distinct pigmented foci; visible to the naked eye, which continue to expand in diameter and can be maintained in this culture system for up to 22 weeks. RPE foci were manually isolated using sterile microblades (Interfocus) and collected in TLP medium. Pooled foci were washed with PBS −/− and incubated at 37 ± 2 °C with Accutase (Sigma) until a cell suspension is observed. The suspension was then passed through a 70-µm cell strainer (Corning), washed in TLP medium and counted. The cells were plated on CELLstart-coated (Life Technologies) 48-well plates at 4.8 × 10 4 cells/well. Cells were maintained on a twice-weekly media replenishment regimen of TLP medium until they formed a confluent, pigmented cell sheet with cobblestone morphology, generally for a minimum of 5 weeks.
To ensure safety and purity of the RPE, it was essential to exclude the possibility of undifferentiated hESCs being administered to a patient. In situ hybridization was used to assess hESC impurity. Samples of differentiated cells were prepared as a monolayer on microscope slides. Specific oligo probes against LIN28A mRNA were used to evaluate the presence of hESC in the RPE population. LIN28A-stained cells were identified using a nuclear stain. If any LIN28A positive cells were detected, the RPE batch would be rejected. Differentiated RPE was further assessed using immunocytochemistry against the melanosome-specific protein PMEL17 (Dako), an RPE cellular marker. PMEL17 positively stained cells were counted and expressed as a percentage of total cells. Upon testing of cells on representative cell patches, the RPE purity ranged from 99.8 to 100% on positive staining of PMEL17 and no LIN28A-positive cells were detected.
RPE cells were assessed using a light microscope for pigmentation, cobblestone morphology, health and signs of contamination and processed further only if they passed this visual check. Media was removed, cells were washed with PBS −/− , and incubated at 37 ± 2 °C with Accutase for 1-2 h until a cell suspension was observed. The suspension was passed through a 70-µm cell strainer, washed in TLP medium and then counted. Cells were subsequently seeded (1.16 × 10 5 cells/well) into custom manufactured transwells, with polyester membranes coated in plasma-derived human vitronectin. The membrane was 10-µm thick polyethylene terephthalate (PET), with a 0.4-µm pore size at a density of 1 × 10 8 pores/cm 2 (Sterlitech, Kent, Washington, USA). TLP medium was added to the outer well containing the insert, and the plate then incubated at 37 ± 2 °C. The RPE cells were maintained with twice weekly TLP media replenishment until required for drug product manufacture.
On the day of surgery, the transwell was removed from the culture plate and placed directly onto the cutting device. The patch is cut from the membrane and is then placed into the storage solution (0.9% sodium chloride) within the storage container that is then sealed (Fig. 1a) The patch is assessed visually through the clear lid of the storage container for integrity, pigmented cell coverage and viability. The patch was transported out of the GMP facility and transferred to the operating theatre.
Patch cell count. The theoretical cell count on each patch was calculated using an observed cell diameter of 14 µm and this gives ~100,000 cells per patch. To complement this, two patches from preclinical production batches had the cells dissociated and counted and gave counts of 110,000 and 120,000 cells total (i.e., a cell diameter of ~12-13 µm). The theoretical cell count of 100,000 was within the confidence intervals from these two counts, and so was selected.
Immunocytochemistry. Immunostaining was performed as described previously 17 . Briefly, cells were fixed in cold 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer and then blocked and incubated with an appropriate combination of the following primary antibodies: TRA-1-60 (Life Technologies); Ki67 (VectorLabs); CRALBP (Thermo Scientific); PMEL17 (Dako); MERTK (Abcam); ZO-1 (Life Technologies); OTX2 (Millipore); Bestrophin (Millipore) and PEDF (Millipore). They were then incubated in the appropriate secondary antibodies including AlexaFluor 647 conjugated donkey anti-mouse Ig-G (Life Technologies), 594 conjugated donkey anti-rabbit Ig-G (Life Technologies) and Dylight 488 conjugated donkey anti-mouse Ig-M (Startech). Nuclei were stained using Hoechst 33342 (Life Technologies).
Transmission electron microscopy (TEM)
. RPE cells immobilized on a membrane were fixed in Karnovsky's fixative and prepared for TEM as described previously 17 .
PEDF assay. PEDF assay on spent media was completed using a developmental enzyme-linked immunosorbent assay (ELISA; Meso Scale Discovery Platform S600, Mesoscale, USA) according to manufacturer's instructions.
Phagocytosis assay method.
This was based on a previously described method 36 . Purification of photoreceptor outer segments (POS) was performed as described previously 37 . The POS were labeled as described previously 38 . The labeled POS were seeded onto hESC-RPE monolayer patches grown on plasma-derived human vitronectin at 1 × 10 7 POS/ml. In one condition the cells were pre-incubated with 1:50 anti MERTK antibody (ab52968, Abcam) to block phagocytosis for 1 h. The cells were incubated at 37 °C in 5% CO 2 for 6 h. The samples were fixed and stained as described previously 32 . To quantify phagocytosis, three distinct areas per patch of hESC-RPE or hESC-RPE with blocker (MERTK antibody) (n = 3) were imaged blind on the Zeiss 710 confocal. The total number of internalized fluorescent POS were counted in a 135 µm × 135 µm area, using the orthogonal view function.
Mouse teratoma studies. The cells tested were undifferentiated SHEF-1.3 pluripotent hESCs (hereafter 'hESCs'), and SHEF-1.3 hESC-derived RPE ('hESC-RPE'). The cells were grown at a Pfizer facility before transfer to HLS. They were injected into the eyes of NIH III immune-deficient mice (strain Crl:NIH-Lyst bg Foxn1 nu Btk xid , 6-7 weeks old; Charles River, UK) at HLS. The injections were carried out by A.Vu. and A.A. from University College London. Histological and pathological analyses were carried out by HLS, which provided a report on the study.
The second study was conducted as there were fewer tumors in female animals in the first study. It was concluded that this was most likely linked to a decline in cell suspension quality for dosing of the females, rather than an actual sex difference. The second study focused on female animals. In addition, we studied the relative rate of teratoma formation following subretinal, subcutaneous or intramuscular injection of undifferentiated hESCs in female NIH-III mice. In the second study five males were also dosed with undifferentiated hESCs subretinally.
In the third study, under GLP conditions, NIH III mice were administered suspensions of hESC-RPE cells or suspensions of undifferentiated hESCs as a positive tumorigenic control, with all injections being delivered subretinally. Other controls carried out in all the mouse teratoma studies are listed in the tables below. Animals were followed for up to 26 weeks, allowing for the assessment of tumors associated with the administration of the test cells, prior to the animals having an excessive burden of spontaneous tumors. The numbers of animals injected, their sex and the site injected are listed in the following table.
First study: 2-month pilot study of the teratoma formation potential of hESCs in NIH III immune-deficient mice
Test condition
Injected number/sex animals 
Necropsy and histology.
At the end of the study animals were subject to a detailed necropsy, and macroscopic examinations were performed on all treated and control animals. The following tissues were processed for histological examination: abnormal masses, epididymides, eyes, heart, kidneys, liver, lymph nodes (mesenteric, submandibular), optic nerves, ovaries, spleen, sternum with bone marrow, testes. Tissues and organs were collected and fixed in 10% neutral buffer except the eyes and optic nerves, which were fixed in Davidson's fluid. Following histological processing and review, any teratomas or abnormal masses were subject to immunohistochemistry (IHC; anti-human mitochondrial marker staining), using a validated method to confirm whether these were of human or mouse origin.
Pig transplantation feasibility studies. The analysis of the biodistribution data in pig tissues (looking for evidence of human cells in different organs) was done using qPCR by the independent CRO Aros (Aarhus, Denmark) with reports provided. Surgical safety, successful delivery of the RPE patch, local and systemic biodistribution and toxicology were examined in these studies. The pig was selected since the size of the pig eye allowed for the administration of the intended full-size patch and the study of surgical feasibility, biocompatibility and biodistribution. All pig studies described were performed by the same surgeon who operated in the two cases described in the clinical trial (L.d.C.). In the second pig study the same clinical surgical technique was used as in the human trial.
First pig study. In this study, hESC-RPE cells were seeded onto a BD Matrigel (BD Biosciences, Erembodegem, Belgium)-coated polyester membrane and manually implanted as a 1x3-mm membrane into the subretinal space of pig eyes via 20G pars plana vitrectomy, bleb detachment with retinotomy followed by air tamponade. Twenty animals underwent surgery and 12 of these received hESC-RPE cells on the membrane, 2 at each time point, with the remainder receiving a membrane without cells, 1 at each time point except 6 weeks where there were 3 animals. Six of the animals received immunosuppression with oral cyclosporine (650 mg for up to 2 weeks following surgery). Animals were observed, euthanized and enucleated at 2 h, 2 d, 1, 2, 4, and 6 weeks. Eyes were examined by light and electron microscopy. Toxicity. The feasibility of the surgical procedure and the general safety of PF-05206388 was assessed in studies performed in the Large White/Landrace hybrid pigs (in all cases). In the GLP pig study, a group of 5 male and 5 female pigs were administered a patch at a dose of 1 graft in the left eye (approximately 100,000 hESC-RPE cells on a vitronectin-coated polyester membrane) and observed for 26 weeks (6 months). A similarly constituted control group of 5 male and 5 female animals received the vitronectin-coated polyester membrane only. The membrane with or without cells was placed into the subretinal space in all 20 pigs using the same tool and surgical technique as in the clinical trial. Animals received prednisolone (1 mg/kg) orally 7 d before surgery, which continued for 14 d post operatively, intravitreal 4 mg triamcinolone acetonide (TCA) during the surgery, sub-Tenon TCA 40 mg at the end of surgery, and Carprofen (4 mg/kg) was given orally postoperative on day 2 of the study. Eye drops of 0.1% dexamethasone, 0.5% hypromellose and 0.35% neomycin were administered to all the pigs 4 times per day for 17 d post-surgery.
Systemic distribution of cells. The distribution of the hESC-RPE cells was evaluated as part of the pivotal 26-week toxicity study in pigs. The biodistribution was evaluated using qPCR techniques and the human cell markers huGAPD, huPEDF, HSSRY, huPOU5F1, and huOTX1/2 and the pig marker, pigACTB. A total of 60 samples from each animal (5/sex/group) that included the following: adrenal, bone marrow (rib and femur), brain (7 sections), heart (5 sections), kidneys (5 sections), liver (6 sections), lungs (5 sections), lymph nodes (4 nodes, total 8 sections), optic nerve (left and right, proximal and distal to eye), spleen (5 sections), thymus (3 sections) were evaluated. To avoid a high number of false positives, positives in at least two individual human markers in the same sample were required. No animals that received the matrix only had an increase in amplifying human transcripts.
Cell spiking studies. The effect of deliberately spiking hESCs into RPE was assessed. Different proportions (0, 1, 10, 20, 50 or 100%) of hESCs were mixed with dissociated RPE foci (P0 cells), seeded into 96-well plates at 38,000 cells/cm 2 and cultured for 6 weeks (P1 cells) using standard RPE culture conditions. Feeder-free hESC were used for spiking to eliminate counting inaccuracies due to the presence of fibroblast feeder cells. Plates were fixed and stained for TRA-1-60 or PMEL17 and the corresponding no primary antibody controls (n = 4 plates, 1 well/plate stained with each antibody/control). A single-cell suspension of hESCs was also seeded onto Matrigel in mTeSR1 media with ROCK inhibitor 2 d before fixing as a positive control for TRA-1-60 staining.
Flow cytometry. Cells were washed with PBS and treated with Accutase to produce a single-cell suspension, before pelleting and resuspended in 3% BSA/PBS to 1 million/ml. 100,000 cells per sample were incubated on ice for 20 min with IgM-PE isotype control (eBioscience 12-4752-82), TRA-1-60-PE (eBioscience 12-8863-82, PE) or Tra-1-81-PE (eBioscience 12-8883-80) at 1/20 dilution. For propidium iodide (PI) staining, 100 µl 1.5 µM PI (Sigma) was added to 100 µl cells and incubated for 10-15min on ice. Samples were pelleted and resuspended in 150 µl PBS alone (for PI stained samples) or PBS containing 50 nM TOPRO3 (Invitrogen), a dead cell stain, for IgM and TRA-1-60 samples. Samples were run on the Accuri Cflow flow cytometer. Debris, TOPRO3 positive dead cells (except when deliberately analyzing dead populations) and cell doublets were excluded from the analysis.
Immunostaining. For live PI staining, 100 µl 1.5 µM PI (Sigma) in PBS was added to wells containing 100 µl cells/media. After 10 min PI/media was aspirated and replaced with 100 µl 1:10,000 HOESCHT in PBS. Plates were imaged live on the Image Express Micro platform (Molecular Devices Corporation). For immunostaining, cells were fixed with 4% PFA for 20 min, washed with PBS−/− and blocked with 5% NDS in 0.3% triton-X/PBS for 1 h. Primary antibody in 1% NDS/TX/PBS was then applied for a further hour at room temperature. The antibodies used were TRA-1-60 at 1:100 (Abcam 16288, mouse), PMEL17 at 1:25 (DAKO HMB45, mouse monoclonal) or 1:500 Ki67 (Vector K451, rabbit). Wells were washed three times with 1% NDS/TX/PBS and secondary antibody, at 1:200 in 1% NDS/TX/PBS applied for 1 h at room temperature. For TRA-1-60 Jackson anti-mouse IgM (715-485-020) was used, for PMEL17 Invitrogen Alexa Fluor 488 anti-mouse and for Ki67 Alexa Fluor 488 antirabbit was used. Wells were then washed three times with PBS−/− and 1:10,000 HOESCHT applied. These were imaged on the Image Express Micro platform (Molecular Devices Corporation); automated image analysis was performed using MetaExpress software. The best settings for this analysis were determined both by visual observation of the plates and by choosing.
The introducer tool. The patch delivery tool was custom designed and manufactured with the aim of providing protected delivery of the therapeutic patch until its placement into the subretinal space. The device consists of a handle containing a mechanism to advance a flexible rod that passes from the wheel, through the shaft and to the tip where the rod physically pushes the patch out of the tip of the device (Supplementary Fig. 1.) . The rod is advanced by virtue of the wheel on the handle that the surgeon rolls forward to advance the patch out of the device and into position. The patch was loaded manually into the tip by drawing it into place with microforceps.
Clinical trial. Subjects in the trial underwent extensive screening and followup investigations including (i) blood sampling for: hematology: hemoglobin, hematocrit, RBC, platelet, WBC count and differential; Chemistry: urea, creatinine, glucose, calcium, sodium, potassium, chloride, total CO 2 , AST, ALT, total bilirubin, ALP, uric acid, albumin, total protein; HIV, HepB and HepC testing; (ii) urinalysis for pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, microscopy and a drug screen.
A physical examination, including head, ears, eyes, nose, mouth, skin, heart and lung, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems, blood pressure, pulse rate and Electrocardiograms, was also performed. This was a first in man feasibility and safety study. The sample size was decided as an equivalent of a first in man clinical pilot study and the use of 10-12 patients is the convention for this type of trial at Moorfields Eye Hospital. There is no power calculation.
For the mice study there was no formal power calculation. In the first study a total of 100 animals were used. This was a pragmatic choice based on practicality, availability of animals, availability of injected cells and a minimum requirement of at least 10 animals in each of the control groups (The use of a minimum of 10 animals in a group with a cellular treatment and 5 with a non-cellular control continues through all of the animal studies).
The second mouse study was a response to the smaller number of teratomas in female animals. The experiment was repeated with an increased number of female animals to resolve the question of whether this was a valid finding (it was not). The addition of the test situations of Intra-Muscular injection and Subcutaneous injection was a requirement of the regulators scientific review. Once again a minimum of 10 animals was chosen for each cellular test group and 5 for non cell test groups.
The GLP mouse study was based on the signal frequency of the earlier studies but not via a formal power calculation. We pragmatically used twice the number of animals in the hESC -RPE cellular test groups than in the earlier studies. We felt that as there was a teratoma signal with 10 animals in the undifferentiated hESC group from study 2 then it would reasonably be expected to have a signal in twice the number of animals.
In the pig studies the first study was to guage many varied aspects including surgical practicality -the first time this sort of surgery had been done, behavior of the patch in a human size eye, basic cellular and animal survival data and an early indication of the use of immuno-suppression. The number also reflected the cost, complexity and practicalities of completing extensive large animal studies.
The definitive study used 10 pigs in each group as we had used in all of the mouse studies. We felt that 20 repeat animals would be a useful number to show surgical efficiency and complications and that there would still be 10 animals in each test group for patch with RPE and membrane without cells. This was agreed with the regulators before the GLP study was carried out, as a reasonable number to answer the surgical feasibility and complications questions. In terms of biodistibution there were 10 animals and multiple sections from each organ providing a sufficient sample to answer the question of biodistribution. Once again this was agreed prior to the experiment with the regulators.
Data exclusions
Describe any data exclusions.
No data was excluded nature research | life sciences reporting summary June 2017
Replication
Describe whether the experimental findings were reliably reproduced.
This is a first in man first described study. There was no replication study in our research design for the clinical study. The trial is planned for a total of 10 patients as described in point 1. above.
In the mice study the demonstration of teratomas with native hESC was shown in three separate studies and in a total of 158 injected animals -41 animals developed teratomas. The abscence of teratomas in hESC-RPE injected animals was demonstrated in 80 injected animals. Based on the undifferentiated hESC experiments with 41 terratomas from 158 animals we felt that the use of 80 animals for the hESC-RPE experiment was likely show a teratoma if this was a posibility. The hESC-RPE experiment was only completed as a single experiment with 80 repeats.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
There was no randomization in the primary clinical study
In the mice experiments there was no randomization due to the large numbers injected. The CRO presented the animals to the surgeons who carried out the procedure knowing the test cell type or solution. The results were analysed independently of the surgeons and the researchers.
In the GLP (second) pig study there was randomization of which animal received patches with RPE and those without. The surgeon was informed of which patch was to be implanted at the commencement of each surgery.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
There was blinding in the assessment of labeled photo-receptor uptake in the phagocystosis assay as described in the on-line methods: " To quantify phagocytosis, 3 distinct areas per patch of hESC-RPE or hESC-RPE with blocker (MERTK antibody) (n=3) were imaged blind on the Zeiss 710 confocal. The total number of internalized fluorescent POS were then counted in a 135μm x 135μm area, using the orthogonal view function.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
